<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003348</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066327</org_study_id>
    <secondary_id>DUMC-1094-99-6R5</secondary_id>
    <secondary_id>DUMC-929-97-6R3</secondary_id>
    <secondary_id>DUMC-980-98-6R4</secondary_id>
    <secondary_id>NCI-T94-0080</secondary_id>
    <nct_id>NCT00003348</nct_id>
  </id_info>
  <brief_title>Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain</brief_title>
  <official_title>Phase I Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent, Persistent or Progressive Cerebral Anaplastic Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of carmustine plus O(6)-benzylguanine in&#xD;
      treating patients who have recurrent or progressive gliomas of the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of carmustine when administered following&#xD;
      O6-benzylguanine in patients with recurrent, persistent, or progressive cerebral anaplastic&#xD;
      gliomas. II. Characterize the toxic effects associated with this treatment regimen in these&#xD;
      patients. III. Observe patients for clinical antitumor response when treated with this&#xD;
      regimen.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to prior nitrosourea administration (yes or no).&#xD;
      (Prior nitrosoureas stratum closed) An initial cohort of 3 patients per stratum is treated&#xD;
      with intravenous O6-benzylguanine followed approximately 1 hour later by intravenous&#xD;
      carmustine every 6 weeks. Additional cohorts of 3-6 patients are treated with escalating&#xD;
      doses of carmustine until dose limiting toxicity (DLT) is observed. The maximum tolerated&#xD;
      dose is defined as the dose at which no more than 1 of 6 patients experiences DLT. Courses&#xD;
      are repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24-56 patients (12-28 per stratum) will be accrued in 12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1998</start_date>
  <completion_date type="Actual">August 2000</completion_date>
  <primary_completion_date type="Actual">August 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O6-benzylguanine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven recurrent, persistent, or progressive&#xD;
        glioblastoma multiforme or anaplastic astrocytoma diagnosed by biopsy/resection Evaluable&#xD;
        residual disease by MRI or CT scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life&#xD;
        expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3&#xD;
        Platelet count at least 100,000/mm3 Hepatic: SGOT no greater than 2.5 times upper limit of&#xD;
        normal Bilirubin within normal limits Renal: Creatinine no greater than 1.5 mg/dL OR&#xD;
        Creatinine clearance greater than 60 mL/min BUN no greater than 25 mg/dL Pulmonary: DLCO&#xD;
        greater than 80% predicted Other: Not pregnant or nursing Fertile patients must use&#xD;
        effective contraceptive method during and for 2 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks&#xD;
        since prior chemotherapy (6 weeks since prior nitrosourea, procarbazine, or mitomycin) and&#xD;
        recovered Endocrine therapy: Concurrent corticosteroid therapy must be stable for at least&#xD;
        1 week prior to study, if clinically possible Radiotherapy: At least 4 weeks since prior&#xD;
        radiotherapy and recovered Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry S. Friedman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2004</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>O(6)-benzylguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

